The biotechnology company Oxolife S.L. (Spain), the Energy Balance, Puberty and Reproductive Health research group of the University of Cordoba (Spain) and the Human Growth and Reproductive Development research group at Rutgers University, have initiated a triple international collaboration to further investigate the direct mechanisms of the drug OXO-001, designed to improve embryo implantation and to treat infertility associated with Polycystic Ovary Syndrome (PCOS).